ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1779

Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium

Wenxian Zhou1, Hannah Johnson2, Michael Duryee2, Engle Sharp2, Carlos Hunter2, Tate Johnson2, Mabruka Alfaidi2, Daniel Anderson3, Kishore Bidasee2, Geoffrey Thiele2 and Ted Mikuls2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE, 30587964, Durham, NC

Meeting: ACR Convergence 2025

Keywords: autoantigens, Cardiovascular, citrullination, macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1770–1779) Cytokines & Cell Trafficking Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Endothelial cell (EC) dysfunction is a key driver of cardiovascular (CV) complications in rheumatoid arthritis (RA), yet mechanisms underlying EC dysfunction in RA are not fully understood. Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) are post-translational modifications (PTMs) that are increasingly expressed and co-localized in RA tissues. These PTMs synergistically activate macrophages, leading to pro-inflammatory and pro-fibrotic responses in vitro. Our lab recently demonstrated increased expression and co-localization of CIT and MAA in heart tissues of mice with collagen-induced arthritis (CIA) that precedes fibrosis, suggesting a role of these PTMs in promoting local CV inflammation. However, their effects on EC function has not been examined. This study aims to examine whether CIT and MAA induce inflammatory responses in human coronary artery endothelial cells (HCAECs).

Methods: Human U-937 monocytes were differentiated into macrophages (M0 cells) and stimulated for 48 hrs with 25 ng/mL of fibrinogen that was unmodified (FIB) or modified with MAA (FIB-MAA), CIT (FIB-CIT), or MAA and CIT (FIB-MAA-CIT) (Fig. 1). To assess crosstalk, macrophage supernatants were collected, and HCAECs were indirectly stimulated with these supernatants using 25% of total well volume for 8 hrs, 1 day, or 7 days. Concurrently, HCAECs were directly stimulated with FIB, FIB-MAA, FIB-CIT, or FIB-MAA-CIT. After stimulation, HCAEC supernatants were analyzed by ELISA and mRNA measured by qRT-PCR. Statistical analyses were performed using GraphPad Prism and statistical significance was achieved when p< 0.05 and data comparision was conducted by a two-way ANOVA and Tukey’s post hoc test.

Results: Direct EC stimulation with FIB-MAA-CIT resulted in significantly higher levels of mRNA expressions of proinflammatory mediators, including MCP-1, IL-6, ICAM-1, VCAM1 (Fig. 2) and protein secretion (Fig. 3) vs. direct stimulation with FIB-MAA, FIB-CIT, or FIB alone. Interestingly, indirect stimulation of HCAECs with macrophage supernatants showed a similar pattern of inflammatory responses as direct stimulation, but the magnitude of the response was remarkably higher with indirect stimulation compared to direct antigen stimulation, suggesting an additional souble mediator secreted by macrophages contributing to EC activation. Additionally, we observed an earlier activation at mRNA and protein levels for adhesion molecules than peaks for cytokines, confirming cellular cross communications in response to MAA and CIT.

Conclusion: This research provides novel insights into the mechanistic crosstalk between inflammatory cells and coronary EC activation in RA. The data suggest that proteins co-modified with MAA and CIT (enriched in RA tissues) act synergistically to induce inflammatory responses in HCAECs. These inflammatory responses in HCAECs are amplified through macrophage activation and secretion of soluble mediators. In addition to identifying these mediators, further research is needed to examine whether inhibition of MAA, CIT, or downstream signaling pathways attenuates HCAEC activation and reduces CV complications in RA.

Supporting image 1Fig 1. Study schema. HCAECs were either directly stimulated with CIT- and/or MAA-modified FIB or indirectly stimulated with supernatants from antigen-stimulated U-937 macrophages for 8 hours, 1 day, and 7 days. After stimulation, HCAEC supernatants were collected for ELISA, and mRNA was extracted for PCR.

Supporting image 2Fig. 2. PCR Demonstrating Changes in HCAEC Gene Expression Following Direct Antigen Stimulation and Indirect Stimulation with Macrophage Supernatants. 8hr, 1 day, and 7 day mRNA expression was measured for A) MCP-1, B) IL-6, C) ICAM-1, and D) VCAM-1. Relative quotient (RQ) compared to media-cultured negative control cells were calculated and shown in y-axis. Two-way ANOVA was performed and the statistical differences between direct and indirect stimulation were shown in *: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Statistical differences between CIT- and/or MAA-modified FIB compared with unmodified FIB were shown in ¶: ¶ p < 0.05; ¶¶ p < 0.01; ¶¶¶ p < 0.001; ¶¶¶¶ p < 0.0001.

Supporting image 3Fig. 3. ELISA Demonstrating Changes in HCAEC Protein Secretion Following Direct Antigen Stimulation and Indirect Stimulation with Macrophage Supernatants. 8hr, 1 day, and 7 day protein concentrations in supernatants were measured for A) MCP-1, B) IL-6, C) ICAM-1, and D) VCAM-1. Two-way ANOVA was performed and the statistical differences between direct and indirect stimulation were shown in *: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Statistical differences between CIT- and/or MAA-modified FIB compared with unmodified FIB were shown in ¶: ¶ p < 0.05; ¶¶ p < 0.01; ¶¶¶ p < 0.001; ¶¶¶¶ p < 0.0001.


Disclosures: W. Zhou: None; H. Johnson: None; M. Duryee: None; E. Sharp: None; C. Hunter: None; T. Johnson: None; M. Alfaidi: None; D. Anderson: None; K. Bidasee: None; G. Thiele: None; T. Mikuls: Amgen, 2, 5, Merck/MSD, 1, Olatech Therapeutics, 1, UCB, 1.

To cite this abstract in AMA style:

Zhou W, Johnson H, Duryee M, Sharp E, Hunter C, Johnson T, Alfaidi M, Anderson D, Bidasee K, Thiele G, Mikuls T. Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/citrullinated-and-malondialdehyde-acetaldehyde-modified-fibrinogen-activates-macrophages-and-induces-inflammatory-responses-in-coronary-endothelium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrullinated-and-malondialdehyde-acetaldehyde-modified-fibrinogen-activates-macrophages-and-induces-inflammatory-responses-in-coronary-endothelium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology